SALT LAKE CITY, May 16, 2012 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today the presentation of a study at the American Society of Clinical Oncology® (ASCO) Annual Meeting, including the complete results from a study titled, “Use of a proliferation-based mRNA signature to predict outcome in early-stage non-small cell lung adenocarcinoma.” The abstract of the presentation (#7023) is available on the ASCO Meeting website, www.asco.org.
